US Patent 7807390 G-protein coupled receptor ligands and methods
Patent 7807390 was granted and assigned to Schering on October, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+303 characters)
Article
Patent abstract
The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
Edits on 16 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07807390 G-protein coupled receptor ligands and methods US Patent 7807390 G-protein coupled receptor ligands and methods
Infobox
Patent Number
0780739000
Patent Number
780739000
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078073900
Date of Patent
October 5, 2010
0Patent Application Number
119702760
Date Filed
January 7, 2008
0Official Website
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078073900
Date of Patent
October 5, 2010
0Patent Application Number
119702760
Date Filed
January 7, 2008
0Official Website
Patent Primary Examiner
Edits on 3 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 5 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07807390 G-protein coupled receptor ligands and methods
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07807390
Date of patent
October 5, 2010
Patent application number
11970276
Date Filed
January 7, 2008
Patent primary examiner
Find more entities like US Patent 7807390 G-protein coupled receptor ligands and methods
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
